Rimegepant - Pfizer
Alternative Names: BHV-3000; BMS-927711; NURTEC ODT; Rimegepant orally disintegrating tablet - Pfizer; Rimegepant sulfate - Pfizer; Rimegepant Zydis® ODT - Pfizer; Rimegepant Zydis® oral fast-dissolve tablet - Pfizer; VYDURA; VyduraLatest Information Update: 24 Jun 2025
At a glance
- Originator Bristol-Myers Squibb
- Developer Pfizer
- Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antimigraines; Antipsoriatics; Carbamates; Cycloheptanes; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II/III Rhinosinusitis; Temporomandibular joint dysfunction syndrome
- Phase II Plaque psoriasis; Trigeminal neuralgia
Most Recent Events
- 11 Mar 2025 Pfizer initiates enrolment in a phase III trial In Migraine (Prevention, In women with menstrual migraine) in USA (NCT06641466; 700377385)
- 18 Nov 2024 Weill Medical College of Cornell University and Biohaven Pharmaceuticals completes a phase II trial in Plaque psoriasis in USA (PO) (NCT04629950)
- 15 Nov 2024 Phase-III clinical trials in Migraine (Prevention, In adolescents) in USA, Japan (PO) (NCT06616194)